Dresner Partners Advises Haemoscope in Divestiture of its TEG® Thrombelastograph® Hemostasis Analyzer Business
|Tuesday, November 20, 2007|
CHICAGO – November 20, 2007 – Dresner Partners, a leading NASD middle-market investment bank, announced today that it acted as exclusive financial advisor to Haemoscope Corporation in the divestiture of its TEG® Thrombelastograph® Hemostasis Analyzer business. Late last month, Haemonetics Corporation announced its intent to acquire the TEG business from Haemoscope for $44 million in cash. The acquisition closed today.
Eli Cohen, Haemoscope's Chairman and CEO, said, "The Dresner team recognized the shareholder value that could be unlocked through the sale of the TEG business to a strategic partner. The team structured a transaction that was in the best interests of Haemoscope’s employees, customers and shareholders."
“Advising Haemoscope in this transaction exemplifies the capabilities of our rapidly growing health care practice,” said Steven M. Dresner, president of Dresner Partners. “The principals of Haemoscope, Eli Cohen and Gabe Raviv, have been important clients of our firm. This transaction represents a significant milestone for the shareholders of Haemoscope, while also providing a strong foundation for the development of exciting new generations of product in the hemostasis marketplace.”
About Dresner Partners
# # #